JNJ Fair Value — Johnson & Johnson

Drug Manufacturer · Institutional-depth multi-model valuation on Equity Rank

Current Price
$250.80
Consensus Fair Value
$179.15
Margin of Safety
-28.6%

How JNJ's valuation models agree

Equity Rank computed model fair value for JNJ from 9 independent valuation methods with sufficient data. 3 place fair value above the current price of $250.80, and 6 place it below. The model-blended estimate lands at $179.15 — a model fair value differential of 28.6% below the current price under these model assumptions. The larger group places fair value below the current price.

Models: FV above price
3
Models: FV below price
6
Models compared
9

Each method (DCF, Graham Number, EPV, Three-Stage DCF, DDM, Residual Income, Justified Price-to-Book, and more) is weighted by historical sector accuracy. Model-derived and informational only — not investment advice.

JNJ fundamental profile

Equity Rank's fundamental strength composite scores JNJ at 72.7/100 (B+, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +4.7% per year and gross margin has moved +3.5 pp. Its SAVE composite score has moved -0.2 over the past 30 days.

A composite quality metric for research context — not a rating, recommendation, or directional signal.

About JNJ

Johnson & Johnson (JNJ) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.

Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.

Related Stocks in Drug Manufacturer

UNH · PFE · ABBV · MRK · LLY

Research Tools

Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator